Neurocrine Biosciencesvs.Vertex Pharmaceuticals
NBIX vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 6.9× larger than Neurocrine Biosciences by market cap; year to date, Neurocrine Biosciences leads (+24.9% vs +7.1%).
Side by side
| NBIX | VRTX | |
|---|---|---|
| Market cap | $17.7B | $121B |
| Price | $177.11 | $485.39 |
| Today | −1.9% | −2.2% |
| Return YTD | +24.9% | +7.1% |
| Return 1Y | +31.3% | +1.2% |
| P/E | 26.4 | 27.9 |
| P/S | 5.7 | 9.9 |
| P/B | 5.2 | 6.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →Vertex PharmaceuticalsVRTX
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Full VRTX profile →More comparisons in Biotech & innovation
See where NBIX and VRTX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →